ANI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 10, 2024 at 07:09 am EDT
Share
ANI Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 137.43 million compared to USD 106.79 million a year ago. Net income was USD 18.21 million compared to USD 1.44 million a year ago.
Basic earnings per share from continuing operations was USD 0.84 compared to USD 0.06 a year ago. Diluted earnings per share from continuing operations was USD 0.82 compared to USD 0.06 a year ago.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.